Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere, Cisplatin, and Irinotecan in Advanced Esophageal and Gastric Cancer
NCT00165464Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2001
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and irinotecan in esophageal cancer and gastric cancer (GC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate. Started Aug 2001; status: completed.
02
Drugs
docetaxelcisplatinirinotecan
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT00165464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165464.